Androstanolone enanthate
Appearance
![]() | |
Clinical data | |
---|---|
Trade names | Anaboleen Depot |
Other names | Stanolone enanthate; Dihydrotestosterone enanthate; DHT enanthate; Dihydrotestosterone heptanoate; DHTH; 5α-Androstan-17β-ol-3-one 17β-heptanoate |
Routes of administration | Intramuscular injection |
Drug class | Androgen; Anabolic steroid; Androgen ester |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C26H42O3 |
Molar mass | 402.619 g·mol−1 |
3D model (JSmol) | |
| |
|
Androstanolone enanthate (brand name Anaboleen Depot), also known as stanolone enanthate or dihydrotestosterone heptanoate (DHTH), as well as 5α-androstan-17β-ol-3-one 17β-heptanoate, is a synthetic androgen and anabolic steroid and a dihydrotestosterone ester.[1][2] It is used as an injectable and acts as a prodrug of androstanolone (stanolone, dihydrotestosterone, DHT). The drug has been studied in and found to be effective in the treatment of gynecomastia in boys and adult men.[3][4][5] The pharmacology of androstanolone enanthate has been studied.[6][7]
See also
References
- ^ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 640–. ISBN 978-1-4757-2085-3.
- ^ I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 261–. ISBN 978-94-011-4439-1.
- ^ Swerdloff, Ronald S.; Wang, Christina (1998). "Dihydrotestosterone: A rationale for its use as a non-aromatizable androgen replacement therapeutic agent". Baillière's Clinical Endocrinology and Metabolism. 12 (3): 501–506. doi:10.1016/S0950-351X(98)80267-X. ISSN 0950-351X. PMID 10332569.
- ^ Eberle AJ, Sparrow JT, Keenan BS (1986). "Treatment of persistent pubertal gynecomastia with dihydrotestosterone heptanoate". J. Pediatr. 109 (1): 144–9. doi:10.1016/s0022-3476(86)80596-0. PMID 3088241.
- ^ Swerdloff, Ronald S.; Dudley, Robert E.; Page, Stephanie T.; Wang, Christina; Salameh, Wael A. (2017). "Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels". Endocrine Reviews. 38 (3): 220–254. doi:10.1210/er.2016-1067. ISSN 0163-769X. PMC 6459338. PMID 28472278.
- ^ Keenan, Bruce S.; Eberle, Andrea J.; Sparrow, James T.; Greger, Nancy G.; Panko, Walter B. (1987). "Dihydrotestosterone Heptanoate: Synthesis, Pharmacokinetics, and Effects on Hypothalamic-Pituitary-Testicular Function". The Journal of Clinical Endocrinology & Metabolism. 64 (3): 557–562. doi:10.1210/jcem-64-3-557. ISSN 0021-972X. PMID 3546348.
- ^ Coutts SB, Kicman AT, Hurst DT, Cowan DA (November 1997). "Intramuscular administration of 5 alpha-dihydrotestosterone heptanoate: changes in urinary hormone profile". Clin. Chem. 43 (11): 2091–8. doi:10.1093/clinchem/43.11.2091. PMID 9365393.